## Dominic Way

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2673152/publications.pdf

Version: 2024-02-01

12	345	7	10
papers	citations	h-index	g-index
12	12	12	435
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	COVID-19: Reflections on trust, tradeoffs, and preparedness. Journal of Risk Research, 2020, 23, 838-848.	2.6	138
2	The Evolving Field of Risk Communication. Risk Analysis, 2020, 40, 2240-2262.	2.7	78
3	Transparency in Europe: A Quantitative Study. Risk Analysis, 2015, 35, 1210-1229.	2.7	45
4	Pharmaceutical Benefit–Risk Communication Tools: A Review of the Literature. Drug Safety, 2017, 40, 15-36.	3.2	24
5	Transparency and trust in the European pharmaceutical sector: outcomes from an experimental study. Journal of Risk Research, 2016, 19, 1082-1103.	2.6	20
6	Medicines transparency at the European Medicines Agency (EMA) in the new information age: the perspectives of patients. Journal of Risk Research, 2016, 19, 1185-1215.	2.6	19
7	Transparency of medicines data and safety issues–a European/US study of doctors' opinions: what does the evidence show?. Journal of Risk Research, 2016, 19, 1172-1184.	2.6	8
8	Effects of public trust on behavioural intentions in the pharmaceutical sector: data from six European countries. Journal of Risk Research, 2021, 24, 645-672.	2.6	8
9	Pharmaceutical Benefit–Risk Perception and Age Differences in the USA and Germany. Drug Safety, 2020, 43, 1141-1156.	3.2	3
10	Transparency and trust in the European pharmaceutical sector: a Commentary. Journal of Risk Research, 2016, 19, 1120-1128.	2.6	2
11	Pharmaceutical Benefit-Risk Perception and Older Age: A Pilot Study. Therapeutic Innovation and Regulatory Science, 2019, , 216847901987076.	1.6	0
12	Pharmaceutical Benefit-Risk Perception and Older Age: A Pilot Study. Therapeutic Innovation and Regulatory Science, 2020, 54, 645-657.	1.6	0